愛爾康 ALC 深 滬
已收盤 02-06 16:00:00 美东时间
78.83
+0.460
+0.59%
華盛通- 最 高78.885
- 今 開77.44
- 成交量 208.87万股
- 最 低 77.44
- 昨 收 78.37
- 總市值 387.21亿
- 52周最高 98.8664
- 市盈率 靜 38.53
- 換手率 0.43%
- 52周最低 71.55
- 委 比 47.06%
- 總股本 4.91亿
- 歷史最高 100.7664
- 量 比 0.96
- 振 幅 1.84%
- 歷史最低 38.2212
- 每 手 1
- 風險率 6.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alcon Targets Faster Growth In 2026 With New Cataract Surgery Systems
William Blair initiates Alcon with a Market Perform rating, citing strong pipeline, UNITY platform launches, and rising consumables growth, while noting the stock already trades at a premium.
01-31 02:00
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Stifel Downgrades Alcon to Hold, Lowers Price Target to $80
Stifel analyst Thomas Stephan downgrades Alcon (NYSE:ALC) from Buy to Hold and lowers the price target from $85 to $80.
01-09 22:22
STAAR Surgical To Terminate Alcon Merger After Failing To Secure Stockholder Approval
STAAR Intends to Terminate Alcon Merger AgreementSTAAR Surgical Company (NASDAQ:STAA) ("STAAR"), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision
01-06 21:48
Alcon Exercises Merger Rights, Forcing STAAR Surgical To Adjourn Shareholder Vote To January 6, 2026
Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders STAAR Special Meeting of Stockholders Adjourned to January 6, 2026 LAKE FOREST, Calif., December 19, 2025 – STAAR Surgical
2025-12-20 00:44
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
Broadwood Slams STAAR–Alcon Deal as Flawed and Unfair to Shareholders
Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood," "we," "us" or "our") today reacted to the proxy statement supplement filed by STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) with
2025-12-11 20:12
Broadwood Partners, 30.2% Stake Holders, Opposes Alcon's STAAR Surgical Acquisition; Says Calls Price Bump "Insufficient" And Sale Process Deeply Flawed
Notes That Price Bump Is Further Evidence That the Original Sale Process Was Horribly Flawed and Failed to Maximize Shareholder ValueNew Price Is Approximately Half the Price Offered by Alcon Twice in 2024; STAAR's
2025-12-10 02:05
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
